Search

everythinglearnresearchcommunity

for

Search:↓

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

The user is considering postponing a scheduled hair transplant to see if finasteride and minoxidil treatments improve hair growth. Another user suggests waiting several months to assess the effectiveness of the medications before deciding on surgery.

A user reported worsening hair shedding and thinning after 6 months of daily dutasteride, despite also using minoxidil, bicalutamide, and recently adding RU58841. They are considering stopping dutasteride due to lack of improvement.

The post discusses a user's hair loss treatment involving Dutasteride 2.5 mg 5 times per week, Finasteride 1mg 4 times per week, RU58841 daily, and Minoxidil twice daily. A reply suggests that the combination is excessive, particularly the use of both Dutasteride and Finasteride, and labels it as a "chemical castration protocol".

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

A user shared progress pictures 12 months after a hair transplant and daily use of dutasteride. The conversation discusses the quality of comparison photos and the use of hair fibers.

A 26-year-old is considering switching from a regimen of minoxidil, finasteride, and RU58841 to possibly include pyrilutamide due to insufficient results in slowing hair loss. They are seeking advice on whether to add pyrilutamide or replace RU58841 with it, considering cost and effectiveness.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.

A user switched from finasteride and minoxidil to dutasteride and increased their oral minoxidil dose to 5mg daily, resulting in significant hair regrowth in three months. They stopped using tretinoin and reported minimal hair shedding and noticeable new hair growth.

Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user experienced initial success with topical minoxidil and dutasteride mesotherapy but is now losing more hair and unsure if it's due to shedding or ineffective treatment. They are considering whether to try a different approach.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

The user is considering switching from a 5% minoxidil and 0.1% finasteride mix to a combination of 5% minoxidil, 0.1% finasteride, 0.01% tretinoin, and 1.5% azelaic acid due to low regrowth success. They are seeking advice on whether to use the new mix at night and continue the old mix in the morning or try oral minoxidil in the morning.

After over a year of treatment with daily oral dutasteride and minoxidil, plus injected dutasteride every 6 months, the user is happy with the increased thickness of their hair and improved self-esteem, although scalp visibility remains. They encourage others to follow similar treatments for long-term hair maintenance.

The user has been using finasteride and dutasteride mesotherapy for 2 months with no noticeable change in hair loss or shedding. They experienced side effects from oral minoxidil and suspect seborrheic dermatitis.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

Dutasteride mesotherapy may stabilize hair loss and improve hair without significantly affecting serum DHT levels, but it can still have systemic effects. Users discuss using topical and oral dutasteride, with some experiencing side effects and considering hair transplants.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The user experienced significant hair regrowth on temples and beard using a combination of Dutasteride, Tretinoin, and topical Minoxidil, but stopped oral Minoxidil due to heart pain. The user switched from Finasteride to Dutasteride due to aggressive hair loss.

Oral minoxidil, finasteride, and dutasteride are being used to treat hair loss, but results are limited, leading to consideration of a hair transplant. The user plans to continue medication for another year before deciding on further action.

Minoxidil alone is just as effective as when combined with tretinoin and azelaic acid for hair loss. People adding tretinoin and azelaic acid to minoxidil may not see the expected benefits.

The user experienced hair improvement after one year using 0.5 mg oral dutasteride, 5 mg oral minoxidil, and ketoconazole shampoo three times a week. They noticed progress after initial shedding and attribute changes to medication adjustments.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.